FORX-428 / FoRx Therap - LARVOL DELTA

FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug FORX-428 Targeting DNA Damage Response (GlobeNewswire) - "An initial data readout from the trial is expected by mid-2026....FORX-428 received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) on June 13, the first patient first visit (FPFV) was on July 22 and the first patient was dosed on August 6."

P1 data • Trial status • Solid Tumor

FoRx Therapeutics...announced the dosing of the first patient in a first-in-human clinical study of FORX-428 (The Manila Times) - "An initial data readout from the trial is expected by mid-2026. The open-label study, initially taking place in the United States, is evaluating safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors who have exhausted standard-of-care options...FORX-428 received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) on June 13, the first patient first visit (FPFV) was on July 22 and the first patient was dosed on August 6."

P1 data • Trial status • Solid Tumor

FoRx Therapeutics Appoints Chief Medical Officer and Provides an Update on Its Lead Development Candidate (Businesswire) - "...the Company provided an update on its lead development candidate, FORX-428. The compound is an inhibitor of PARG (Poly(ADP-ribose) glycohydrolase) and is being developed for the treatment of solid tumors. FoRx Therapeutics reports significant progress towards IND (Investigational New Drug) submission for FORX-428 and anticipates clearance from the FDA by mid-2025."

IND • Solid Tumor

FoRx-06-428 is a novel PARG inhibitor with potent anti-tumor efficacy in preclinical cancer models (AACR 2024) - "Sensitivity to PARG inhibition is partly driven by distinct genomic instabilities, such as defects in homologous recombination (HR) repair, however the activity of PARG inhibitors is also influenced by aberrations in other cancer-relevant pathways. This report represents the first disclosure of the pharmacological characterization of FoRx-06-428 and highlights the value of PARG inhibition as a novel targeted approach to treat DNA repair-deficient cancers."

Preclinical • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • PARP1